The government is asking pharma companies to introduce additional measures, over and above the stockpiles already in place, in the event of a ‘no-deal’ Brexit.
UK biotech Mereo BioPharma is merging with Californian biotech OncoMed in an all-stock deal that swells its pipeline and gives it a potential licensing deal with Celgene.
Gene and cell therapy firm Oxford Biomedica is to invest £4 million to build digital and robotics capabilities that will help manufacture the next generation of cutting edge therapies.
